Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Opin Cell Biol. 2009 Apr;21(2):304-10. doi: 10.1016/j.ceb.2009.02.001. Epub 2009 Mar 26.

Linking somatic genetic alterations in cancer to therapeutics.

Author information

1
Oncology Disease Area, Novartis Institutes for BioMedical Research, Emeryville, CA 94608, USA. Darrin.Stuart@novartis.com

Abstract

Somatic genetic alterations provide the foundation for the evolution of human tumors as well as significant opportunity for therapeutic intervention. This review will cover the growing list of examples where somatic genetic alterations have successfully been coupled with a targeted agent resulting in positive clinical outcome. For example, recent data from randomized clinical trials support the earlier observations that EGFR mutant lung tumors are most likely to respond to EGFR kinase inhibitors, while wild-type tumors rarely respond. Emerging data indicate that this principle may also apply to such intractable diseases such as melanoma which has long been refractory to conventional chemotherapeutics.

PMID:
19328671
DOI:
10.1016/j.ceb.2009.02.001
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center